mRNA |
Lisitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.092 |
0.01 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.084 |
0.01 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.01 |
mRNA |
QS11 |
GDSC1000 |
pan-cancer |
AAC |
-0.094 |
0.01 |
mRNA |
Nutlin-3 |
CCLE |
pan-cancer |
AAC |
0.12 |
0.01 |
mRNA |
JW-7-52-1 |
GDSC1000 |
pan-cancer |
AAC |
-0.14 |
0.01 |
mRNA |
MG-132 |
GDSC1000 |
pan-cancer |
AAC |
-0.13 |
0.01 |
mRNA |
PF-3758309 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.01 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.081 |
0.01 |
mRNA |
MLN2480 |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.01 |